The Risk of Cardiovascular Diseases in Axial Spondyloarthritis. Current Insights

There is an increased cardiovascular (CV) risk in axial spondyloarthritis (axSpA), leading to increased CV mortality and morbidity in these patients. The factors that may explain this enhanced CV risk in axSpA are multiple, including traditional CV risk factors such as smoking, but also the inflamma...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Eric Toussirot
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	ankylosing spondylitis spondyloarthritis cardiovascular risk cardiovascular risk factors atherosclerosis Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/66187b3dab6242fa934d5124bea97556
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:66187b3dab6242fa934d5124bea97556
record_format	dspace
spelling	oai:doaj.org-article:66187b3dab6242fa934d5124bea975562021-11-08T06:00:10ZThe Risk of Cardiovascular Diseases in Axial Spondyloarthritis. Current Insights2296-858X10.3389/fmed.2021.782150https://doaj.org/article/66187b3dab6242fa934d5124bea975562021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fmed.2021.782150/fullhttps://doaj.org/toc/2296-858XThere is an increased cardiovascular (CV) risk in axial spondyloarthritis (axSpA), leading to increased CV mortality and morbidity in these patients. The factors that may explain this enhanced CV risk in axSpA are multiple, including traditional CV risk factors such as smoking, but also the inflammatory process and probably the use of non-steroidal anti-inflammatory drugs (NSAIDs). The CV involvement of axSpA may be detected at an early and pre-clinical stage, using non-invasive techniques. While NSAIDs play a deleterious role in the CV risk of axSpA, TNF inhibitors seem to have a beneficial impact, but this remains to be demonstrated in specific clinical studies. More data are needed to determine the potential effects of IL-17 inhibitors on the CV risk of axSpA. CV comorbidity has been mainly assessed in the radiographic form of axSpA, while limited data are available in patients with the non-radiographic form. The current management of axSpA must consider this CV comorbidity according to the EULAR recommendations. Rheumatologists play a determinant role in the detection of CV risk and current management of these patients is focused on the control of disease activity, suppression of inflammation, screening for and management of traditional CV risk factors, as well as the restriction of NSAID use.Eric ToussirotEric ToussirotEric ToussirotEric ToussirotFrontiers Media S.A.articleankylosing spondylitisspondyloarthritiscardiovascular riskcardiovascular risk factorsatherosclerosisMedicine (General)R5-920ENFrontiers in Medicine, Vol 8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	ankylosing spondylitis spondyloarthritis cardiovascular risk cardiovascular risk factors atherosclerosis Medicine (General) R5-920
spellingShingle	ankylosing spondylitis spondyloarthritis cardiovascular risk cardiovascular risk factors atherosclerosis Medicine (General) R5-920 Eric Toussirot Eric Toussirot Eric Toussirot Eric Toussirot The Risk of Cardiovascular Diseases in Axial Spondyloarthritis. Current Insights
description	There is an increased cardiovascular (CV) risk in axial spondyloarthritis (axSpA), leading to increased CV mortality and morbidity in these patients. The factors that may explain this enhanced CV risk in axSpA are multiple, including traditional CV risk factors such as smoking, but also the inflammatory process and probably the use of non-steroidal anti-inflammatory drugs (NSAIDs). The CV involvement of axSpA may be detected at an early and pre-clinical stage, using non-invasive techniques. While NSAIDs play a deleterious role in the CV risk of axSpA, TNF inhibitors seem to have a beneficial impact, but this remains to be demonstrated in specific clinical studies. More data are needed to determine the potential effects of IL-17 inhibitors on the CV risk of axSpA. CV comorbidity has been mainly assessed in the radiographic form of axSpA, while limited data are available in patients with the non-radiographic form. The current management of axSpA must consider this CV comorbidity according to the EULAR recommendations. Rheumatologists play a determinant role in the detection of CV risk and current management of these patients is focused on the control of disease activity, suppression of inflammation, screening for and management of traditional CV risk factors, as well as the restriction of NSAID use.
format	article
author	Eric Toussirot Eric Toussirot Eric Toussirot Eric Toussirot
author_facet	Eric Toussirot Eric Toussirot Eric Toussirot Eric Toussirot
author_sort	Eric Toussirot
title	The Risk of Cardiovascular Diseases in Axial Spondyloarthritis. Current Insights
title_short	The Risk of Cardiovascular Diseases in Axial Spondyloarthritis. Current Insights
title_full	The Risk of Cardiovascular Diseases in Axial Spondyloarthritis. Current Insights
title_fullStr	The Risk of Cardiovascular Diseases in Axial Spondyloarthritis. Current Insights
title_full_unstemmed	The Risk of Cardiovascular Diseases in Axial Spondyloarthritis. Current Insights
title_sort	risk of cardiovascular diseases in axial spondyloarthritis. current insights
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/66187b3dab6242fa934d5124bea97556
work_keys_str_mv	AT erictoussirot theriskofcardiovasculardiseasesinaxialspondyloarthritiscurrentinsights AT erictoussirot theriskofcardiovasculardiseasesinaxialspondyloarthritiscurrentinsights AT erictoussirot theriskofcardiovasculardiseasesinaxialspondyloarthritiscurrentinsights AT erictoussirot theriskofcardiovasculardiseasesinaxialspondyloarthritiscurrentinsights AT erictoussirot riskofcardiovasculardiseasesinaxialspondyloarthritiscurrentinsights AT erictoussirot riskofcardiovasculardiseasesinaxialspondyloarthritiscurrentinsights AT erictoussirot riskofcardiovasculardiseasesinaxialspondyloarthritiscurrentinsights AT erictoussirot riskofcardiovasculardiseasesinaxialspondyloarthritiscurrentinsights
_version_	1718442914839789568

The Risk of Cardiovascular Diseases in Axial Spondyloarthritis. Current Insights

Ejemplares similares